Foghorn Therapeutics Inc. - ESG Rating & Company Profile powered by AI
The report of Foghorn Therapeutics Inc. incorporates intelligence from across the web as well as from public filings by Foghorn Therapeutics Inc.. This ESG score for Foghorn Therapeutics Inc. indicates its transparency towards the United Nations Sustainable Development Goals. This Disclosure rating includes seventeen United Nations Sustainable Development Goals including: 'Affordable & Clean Energy', 'Decent Work & Economic Growth' and 'Life below Water'.
Foghorn Therapeutics Inc. in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.0; made up of an environmental score of 4.0, social score of 4.8 and governance score of 3.2.
4.0
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 989 | Spectrum Pharmaceuticals Inc | 4.1 | High |
| 989 | Tricida Inc | 4.1 | High |
| 1004 | Foghorn Therapeutics Inc. | 4.0 | High |
| 1004 | Can B Corp | 4.0 | High |
| 1004 | CLS Holdings USA Inc | 4.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Foghorn Therapeutics Inc. have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. disclose current and historical energy intensity?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. report the average age of the workforce?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. disclose its ethnicity pay gap?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. disclose cybersecurity risks?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. offer flexible work?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. conduct supply chain audits?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Foghorn Therapeutics Inc. conduct 360 degree staff reviews?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. disclose the individual responsible for D&I?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. disclose water use targets?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. have careers partnerships with academic institutions?
Sign up for free to unlockDid Foghorn Therapeutics Inc. have a product recall in the last two years?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. disclose incidents of discrimination?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Foghorn Therapeutics Inc. issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. disclose parental leave metrics?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. disclose the pay ratio of women to men?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Foghorn Therapeutics Inc. involved in embryonic stem cell research?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. disclose its waste policy?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. report according to TCFD requirements?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. disclose energy use targets?
Sign up for free to unlockDoes Foghorn Therapeutics Inc. disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Foghorn Therapeutics Inc. have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Foghorn Therapeutics Inc.
These potential risks are based on the size, segment and geographies of the company.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. Foghorn Therapeutics Inc. has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel therapeutics based on disruptors of a specified transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.